Hepatitis C Virus

Shorter course of combination therapy approved in E.U. for some hepatitis C patients

Published in Anti-Infectives Week, October 31st, 2005

Schering-Plough Corporation (SGP) announced that the European Commission has approved revised dosing instructions allowing for a shorter, 24-week course of Peg-Intron (1.5 mcg/kg once weekly) and Rebetol (800-1,200 mg daily) combination therapy.

The revised dosing instructions are for use among a subgroup of patients with chronic hepatitis C virus (HCV) genotype 1 infection and low viral load (less than 600,000 IU/ml) who have achieved rapid virologic response, defined as undetectable virus (HCV-RNA negative) at week 4 of treatment that is maintained through week 24. The approval follows a positive opinion granted on July 28, 2005, by the Committee for Medicinal...

Want to see the full article?

Purchase this article for only $3.00

We're a pay-per-view site for premium content. If you'd like to purchase this article, it's only $3.00.

Welcome to NewsRx!

Learn more about a six-week, no-risk free trial of Anti-Infectives Week

Source: Anti-Infectives Week (2005-10-31)

NewsRx is Social

Top Medical Newsletters

Awards

Best Health/Healthcare Content, 2012
Best Health/Healthcare Content, 2011
Best e-Business Site, 2010
Best e-Business Site, 2009
Best e-Business Site, 2008
Best e-Business Site, 2007
Best e-Business Site, 2006
Best Healthcare Content, 2005
Best Overall Internet Site, 2005
Best Interactive Site, 2005

Facts & Stats

NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.

Google 2010 PageRank: #2 Among Top Health News and Media Publications
Google 2010 PageRank: #2 Among Top Science Publications in Biology/Physiology
Google 2010 PageRank: #2 Among Top News and Media for the Business of Pharmaceuticals
Amazon's Alexa 2010 PageRank: #2 News and Media Site for the Pharmaceutical Industry